Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

This trial is testing a combination of cancer treatments for patients with a type of aggressive blood cancer (diffuse large B-cell lymphoma) that carries a specific protein marker called CD30, and whose cancer either did not respond to the first round of treatment or has come back after initial treatment. **You may be eligible if...** - You have been diagnosed with CD30-positive diffuse large B-cell lymphoma (a type of blood cancer where more than 1% of cells carry the CD30 protein marker) - Your cancer either did not respond to first-line chemotherapy (including R-CHOP or similar regimens) or has relapsed after treatment - Your overall health is adequate to tolerate further treatment **You may NOT be eligible if...** - Your lymphoma does not carry the CD30 protein marker - You have had more than one relapse or prior treatment beyond first-line therapy - Your overall health or organ function is too poor for further treatment Talk to your doctor to see if this trial is right for you.